www.uniqure.com/investors-media/press-releases
|
strategische Reorganisation
www.fiercebiotech.com/biotech/...p-gene-therapies-clinic-2027
MK 321 Mio. $ deutlich unter Cash.
Zahlen für Q3/23
Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024
~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected in the first half of 2024
Announced strategic reorganization to advance multiple clinical-stage programs and deliver $180 million of cost savings over the next three years
238 Mio. $ MK vs. 618 Mio. $ Cash (bis Q2/27)
Zahlen für Q1/24
- On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024
- Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024
- Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024
- fund operations into the second quarter of 2027
https://uniqure.gcs-web.com/node/11646/pdf
Theoretisch müsste das Abwärtsrisiko aufgrund der hohen Cashdeckung hier ziemlich limitiert sein. Das CRV sieht für mich aktuell positiv aus.
https://www.biopharmadive.com/news/...uring-sale-gene-therapy/720266/
Durch den Verkauf erhofft sich Uniqure den Cash-Burn um 40 Mio. $ pro Jahr zu senken.
Glückwunsch an alle die dabei waren/sind.
https://www.fiercebiotech.com/biotech/...can-slow-huntingtons-disease
Zahlen für Q2/24
Auf diesem Niveau wirkt die Aktie auf mich wie ein Schnäppchen.
Zahlen für Q3/24
- Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease
- with cash runway through the end of 2027
|